couter

600867.SSTonghua Dongbao Pharmaceutical Co., Ltd.

This is the year Tonghua Dongbao Pharmaceutical has to prove it’s more than a mid-tier player in the drug manufacturing space. The next catalyst — the Q3 2026 earnings announcement on 2026-10-28 — is the first real test, with an anchor of $7.72 and a bull target of $8.63, while the bear fallback sits at $7.37. The market is leaning slightly toward the bear, but the path forward is clear: if the earnings beat expectations and the company shows signs of operational efficiency, the stock could rally toward $8.63. If not, the bear case takes hold, and the stock could fall to $7.37. Either way, the next few months will be a litmus test for whether this company can move beyond its current niche in the specialty and generic drug space.

Nov 20, 2026 — National VBP Policy Impact
Chart by TradingView

The schedule

  • Fri20Nov

    Impact of National Value-Based Pricing Policy on Drug Pricing

  • Thu28Jan
  • Tue16Feb

    GLP-1 and Novel Therapeutics Clinical Trial Outcomes

  • Thu29Apr
  • Thu29Jul
  • Thu28Oct

Past

  • Thu29Oct

    Q3 2026 Earnings Release

  • Fri28Aug

    Actual outcome: Bear · $7.76 at outcome

    The stock closed below the bear floor of $7.45, indicating a bearish outcome. Despite a potential earnings beat, the stock declined due to weak guidance and margin pressure, which overshadowed the results. The price action confirmed the bear case as the market reacted to the lack of confidence in the company's near-term prospects.

    Tonghua Dongbao's H1 2026 earnings print.